QPPV vs. LPPV: How to Structure a Global Pharmacovigilance System for Patient Safety

Pharmaceutical companies operating across multiple markets must monitor medicine safety while meeting different regulatory expectations. A robust pharmacovigilance system requires clear accountability, effective safety monitoring, and coordination between central and local teams.

Compliance requires more than timely adverse event reporting. It demands an integrated pharmacovigilance (PV) framework incorporating effective governance, qualified personnel, scientifically robust benefit-risk evaluation, validated information systems, documented quality management processes and continuous regulatory oversight.

For pharmaceutical companies operating across the European Union (EU), United Kingdom (UK) and international markets, the responsibilities of the Qualified Person Responsible for Pharmacovigilance (QPPV) and locally designated pharmacovigilance personnel are fundamental to the effectiveness of this framework.

This is where Qualified Persons Responsible for Pharmacovigilance (QPPVs) and Local Qualified Persons for Pharmacovigilance (LQPPVs) or Local Contact Persons for Pharmacovigilance (LCPPVs) play important roles. Together, they help pharmaceutical companies strengthen pharmacovigilance compliance, manage safety information and support patient safety across markets.

What Is a QPPV and Why Does It Matter?

A QPPV is a qualified professional responsible for the establishment and maintenance of the Marketing Authorisation Holder’s (MAHs) pharmacovigilance system. Under EU legislation, including Directive 2001/83/EC, Regulation (EC) No 726/2004 and the applicable implementing requirements, MAHs must have an appropriately qualified QPPV permanently and continuously at their disposal.

The QPPV must reside and operate within the EU/European Economic Area (EEA) for an EU pharmacovigilance system. For UK-authorised medicines, the MHRA permits the designated QPPV to reside and operate in either the UK or EU/EEA, subject to the relevant UK requirements.

In accordance with EU GVP Module- I Pharmacovigilance Systems and Their Quality Systems, the QPPV must have adequate authority, access to relevant information and an appropriate position within the organisation to influence PV system performance and regulatory compliance.

Key responsibilities include:

  • Overseeing the pharmacovigilance quality system and safety information.
  • Maintaining oversight of the pharmacovigilance system master file (PSMF).
  • Monitoring compliance with applicable reporting obligations.
  • Supporting regulatory authority communication and inspections.
  • Ensuring emerging safety concerns are appropriately assessed.
  • Exercise sufficient authority to influence corrective actions, resource allocation and decisions affecting patient safety.

A compliant QPPV function is demonstrated not simply through appointment records or a job description, but through evidence of active governance, timely escalation, informed decision-making and continuous oversight of the pharmacovigilance system.

What Is the Role of LPPV and Local PV Contact Person?

A global pharmacovigilance framework must also account for local regulatory requirements. An LPPV, commonly used to describe a local pharmacovigilance representative, can support local safety information management, regulatory communication and coordination with the central PV team.

The term Local Qualified Person for Pharmacovigilance may be used in industry, but the formal title and legal responsibilities vary by jurisdiction. Other terms, such as Local Pharmacovigilance Representative (LPVR), or Local Contact Person (LCP), may be encountered.

For example, in the UK, when the QPPV resides outside the country, the MHRA requires a UK-based National Contact Person for Pharmacovigilance (UK NCP) who reports to the QPPV.

Effective local support helps companies understand market-specific obligations, respond to regulatory queries and ensure relevant safety information reaches the central pharmacovigilance team promptly. These activities must align with the applicable regulatory requirements for MAH/QP/QPPV in each market.

QPPV vs LPPV: How Do They Work Together?

Although their responsibilities differ, QPPV and local PV functions are complementary.

QPPV LPPV / Local PV Contact
Overall PV system oversight Local market support
Pharmacovigilance quality and compliance Local regulatory coordination
PSMF oversight Local safety information flow
Oversight of relevant safety issues and escalation Identification and communication of local safety concerns
Oversight of relevant risk management commitments Implementation and monitoring of local risk minimisation activities
Defined arrangements for QPPV availability and delegation Local continuity arrangements as required

Together, these functions connect global oversight with local regulatory knowledge. This coordination supports timely safety reporting, consistent processes and effective communication with regulatory authorities.

Building a Globally Compliant Pharmacovigilance System:

Establishing a compliant pharmacovigilance system requires more than assigning responsibilities. Companies should focus on six practical areas.

1. Establish clear accountability

Define QPPV responsibilities, local PV activities and reporting lines across the organisation.

2. Maintain an accurate PSMF

The pharmacovigilance system master file (PSMF) should reflect how the system operates, including its organisational structure, quality processes and key safety activities.

3. Standardise core processes

Establish consistent procedures for case management, safety reporting, signal detection and aggregate reporting in pharmacovigilance.

4. Strengthen risk management

A documented risk management plan in pharmacovigilance helps identify important safety concerns and define appropriate risk-minimisation measures.

4. Strengthen risk management

A documented risk management plan in pharmacovigilance helps identify important safety concerns and define appropriate risk-minimisation measures.

5. Adapt to local requirements

Global procedures must accommodate country-specific obligations rather than assume that one approach satisfies every jurisdiction.

6. Maintain inspection readiness

Regular training, audits, documentation reviews and corrective and preventive actions (CAPA) help maintain system effectiveness and demonstrate compliance.

These measures also support pharmacovigilance safety monitoring in clinical trials, where applicable, by helping organisations manage emerging safety information throughout product development.

How QPPV and Local PV Services Strengthen Patient Safety:

Effective pharmacovigilance follows a continuous cycle: detect, evaluate, communicate, mitigate and monitor.

QPPV oversight and local PV coordination help organisations identify emerging safety signals, assess potential risks, communicate important findings and implement appropriate risk-minimisation measures.

Specialised pharmacovigilance services and pharmacovigilance risk management services can support companies in maintaining structured processes, improving documentation and addressing regulatory obligations. The objective is not simply to meet compliance requirements, but to support informed benefit-risk decisions throughout a medicine's lifecycle.

How Sciom Supports Global Pharmacovigilance Compliance?

SCIOM supports pharmaceutical organisations in developing and maintaining structured, quality-driven pharmacovigilance operations aligned with applicable EU, UK and international regulatory expectations.

Through an integrated approach to pharmacovigilance, regulatory affairs and quality management, SCIOM can help MAHs strengthen the interfaces between global safety oversight, local regulatory obligations and operational delivery.

Relevant areas of support include:

  • QPPV and Backup QPPV services.
  • Local pharmacovigilance representation and regulatory contact support.
  • PV system establishment, maintenance and gap assessments.
  • PSMF preparation, review and lifecycle management.
  • ICSR processing, safety surveillance and aggregate reporting.
  • Literature monitoring and safety information management.
  • Risk management and safety governance support.
  • PV quality management, audit preparation and CAPA support.
  • MHRA and EU pharmacovigilance inspection readiness.
  • PV training, vendor oversight and contractual compliance.

By combining regulatory expertise with structured PV processes and proactive quality oversight, SCIOM aims to help pharmaceutical companies maintain compliant, effective and inspection-ready pharmacovigilance systems.

Conclusion: Effective Pharmacovigilance Requires Accountability, Oversight and Local Regulatory Intelligence

The distinction between QPPV and local pharmacovigilance responsibilities is an essential consideration when designing a global PV operating model.

The QPPV provides the overarching regulatory oversight necessary to maintain an effective pharmacovigilance system, while appropriately designated local PV personnel help ensure that jurisdiction-specific safety reporting, regulatory communication and operational obligations are addressed.

However, an effective PV system cannot rely on role designation alone.

It must be supported by accurate PSMF documentation, robust safety surveillance, effective vendor governance, validated computerised systems, comprehensive quality management and demonstrable inspection readiness.

For MAHs operating across the EU, UK and global markets, the objective is not merely regulatory compliance, but a sustainable pharmacovigilance framework capable of continuously evaluating medicine safety and protecting patients throughout the product lifecycle.

Frequently Asked Questions

No. Local PV requirements differ across jurisdictions. Some countries require a formally designated local pharmacovigilance contact, while others rely primarily on the QPPV and central PV system or impose specific local responsibilities. MAHs should maintain a country-specific regulatory requirements assessment defining mandatory appointments, qualifications, residency requirements and reporting responsibilities.

Yes. An MAH may engage an external qualified professional to act as QPPV, provided all applicable regulatory requirements are met. The arrangement should be supported by appropriate contractual provisions, documented responsibilities, effective communication pathways, access to relevant safety information and sufficient authority to influence PV system performance. Outsourcing the QPPV function does not remove the MAH's regulatory accountability.

Potential deficiencies include inadequate QPPV oversight, poor access to safety information, insufficient authority, ineffective escalation processes, incomplete delegation arrangements and limited awareness of significant compliance issues. Inspectors may also identify discrepancies between the PSMF and operational practices or inadequate oversight of contracted service providers. The severity of any finding depends on the specific circumstances and associated risks.

The MAH should establish documented continuity arrangements ensuring uninterrupted performance of critical PV activities. These may include an appropriately qualified deputy, defined delegation arrangements, access to essential systems, regulatory communication pathways and escalation processes. The arrangements should be supported by suitable documentation, training and periodic verification.

While the EU and UK share core GVP principles, differences exist in QPPV location, local contact requirements, PSMF management, safety reporting and regulatory submissions. Following the Windsor Framework (January 2025), UK Category 1 and Category 2 product classifications determine certain applicable PV obligations. MAHs must ensure compliance with the relevant EMA and MHRA requirements.

References

Ready to modernise your pharmacovigilance operations?

Connect with SCIOM PV Experts